Single cell genomics technologies, including single cell RNA sequencing (scRNA-seq) and assay for transposase-accessible chromatin sequencing (scATAC-seq), have revolutionized our understanding of neurodegenerative diseases by revealing cellular heterogeneity that bulk tissue approaches cannot capture. These technologies enable profiling of individual cell types in the brain, identifying rare cell populations, and understanding cell-type specific gene expression changes in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD) [1](https://doi.org/10.1038/s41586-021-03710-0). [@kelley2021]
This mechanism page covers the application of single cell genomics to neurodegeneration research, including cell atlasing, disease-specific transcriptional changes, epigenetic alterations, and therapeutic implications. [@wen2020]
The mammalian brain contains diverse cell types that respond differently to disease processes. Single cell technologies have enabled detailed characterization of: [@mathys2019]
[Neurons](/entities/neurons): Excitatory (glutamatergic) and inhibitory (GABAergic) neurons with distinct subtypes in different brain regions. In neurodegeneration, specific neuronal populations show differential vulnerability. [@zhou2020]
Single cell genomics technologies, including single cell RNA sequencing (scRNA-seq) and assay for transposase-accessible chromatin sequencing (scATAC-seq), have revolutionized our understanding of neurodegenerative diseases by revealing cellular heterogeneity that bulk tissue approaches cannot capture. These technologies enable profiling of individual cell types in the brain, identifying rare cell populations, and understanding cell-type specific gene expression changes in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD) [1](https://doi.org/10.1038/s41586-021-03710-0). [@kelley2021]
This mechanism page covers the application of single cell genomics to neurodegeneration research, including cell atlasing, disease-specific transcriptional changes, epigenetic alterations, and therapeutic implications. [@wen2020]
The mammalian brain contains diverse cell types that respond differently to disease processes. Single cell technologies have enabled detailed characterization of: [@mathys2019]
[Neurons](/entities/neurons): Excitatory (glutamatergic) and inhibitory (GABAergic) neurons with distinct subtypes in different brain regions. In neurodegeneration, specific neuronal populations show differential vulnerability. [@zhou2020]
[Astrocytes](/entities/astrocytes): Support neuronal function through metabolic support, neurotransmitter recycling, and [blood-brain barrier](/entities/blood-brain-barrier) maintenance. Disease-associated astrocyte phenotypes have been identified in AD and PD. [@smajic2022]
[Microglia](/cell-types/microglia-neuroinflammation): Brain-resident immune cells that phagocytose debris and regulate neuroinflammation. Single cell studies have revealed multiple microglia states including disease-associated microglia (DAM) and microglia in a priming phase. [@maniatis2021]
Oligodendrocytes: Myelin-producing cells that support axonal metabolic function. Oligodendrocyte loss and dysfunction contribute to white matter pathology in many neurodegenerative diseases. [@aldalahmah2020]
Oligodendrocyte Precursor Cells (OPCs): Proliferative cells that can generate new oligodendrocytes. Their response to demyelination varies in different disease contexts.
Endothelial Cells and [Pericytes](/cell-types/pericytes): Vascular cells that maintain blood-brain barrier integrity. Vascular dysfunction is an early feature in AD.
Single cell studies in AD have revealed cell-type specific transcriptional changes:
Neurons: Downregulation of synaptic genes, mitochondrial dysfunction signatures, and altered calcium signaling genes. Specific neuronal subsets show tau pathology-related gene expression changes [2](https://doi.org/10.1016/j.cell.2020.08.021).
Astrocytes: Disease-associated astrocytes (DAA) show upregulated GFAP, decreased glutamate transport genes, and altered lipid metabolism. Two distinct astrocyte states have been identified in AD brain.
Microglia: DAM progression from homeostatic to disease-associated states. Early changes include increased expression of complement genes (C1q, C3), followed by upregulation of lipid metabolism genes and lysosomal genes. Microglia from AD brain show distinct transcriptional signatures compared to controls [3](https://doi.org/10.1038/s41586-019-1194-3).
Oligodendrocytes: Reduced myelin gene expression, altered lipid metabolism, and evidence of impaired oligodendrocyte function. OPCs show increased proliferation but reduced differentiation capacity.
Single cell profiling in PD has focused on the substantia nigra pars compacta:
Dopaminergic Neurons: Loss of dopaminergic markers, altered mitochondrial gene expression, and increased stress response genes. Specific subtypes of dopaminergic neurons show differential vulnerability.
Microglia: Activated microglia with increased inflammatory gene expression. Regional variation in microglial activation patterns.
Astrocytes: Altered glutamate handling genes, increased inflammatory signatures.
Motor Neurons: Dysregulated RNA metabolism genes, altered stress response, and excitability changes.
Astrocytes: Toxic astrocyte phenotypes with downregulated glutamate transporters (EAAT1/EAAT2) and increased inflammatory genes.
Microglia: Pro-inflammatory activation with increased complement system genes.
OPCs: Failure to differentiate into mature oligodendrocytes.
Neurons: TDP-43 pathology-associated gene expression changes, including altered RNA splicing and transport genes.
Glia: Astrocyte and microglial activation patterns distinct from AD.
Neurons: Dysregulated transcription factors, altered synaptic genes, and mutant huntingtin-associated transcriptional signatures.
Glia: Astrocyte and microglia activation with altered metabolic support functions.
Single cell chromatin accessibility profiling reveals cell-type specific epigenetic changes:
AD: Neurons show altered accessibility at synaptic gene loci and mitochondrial function genes. Microglia display increased accessibility at inflammatory gene enhancers.
PD: Dopaminergic neurons exhibit modified accessibility at mitochondrial and autophagy-related genes.
ALS: Motor neurons show disrupted chromatin architecture at RNA metabolism and axonal transport gene loci.
scATAC-seq has identified:
| Feature | Bulk RNA-seq | Single Cell RNA-seq |
|---------|--------------|---------------------|
| Resolution | Tissue-level | Single cell |
| Cell type specificity | Lost | Preserved |
| Rare cell detection | Limited | Excellent |
| Cellular heterogeneity | Obscured | Resolved |
| Trajectory analysis | Not possible | Possible |
| Dropout events | Minimal | Frequent |
| Cost per sample | Lower | Higher |
| Throughput | Higher | Lower |